Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBALT: CAR19 T-cells for DLBCL
NCT02431988Phase 1Completed
- Sponsor
- University College London
- Start
- Jun 2016
- Primary completion
- Feb 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Anti-CD19 CAR T-cells (Beijing Doing Biomedical) in diffuse large B-cell lymphoma (DLBCL), sponsored by University College London. Primary endpoints: Feasibility of adequate leucapheresis collection and generation of CAR19 T cells at 1 month, Toxicity evaluation following CAR19 T-cell administration at 1 year and 1 more. Started Jun 2016; status: completed.
02
Drugs
Anti-CD19 CAR T-cells (Beijing Doing Biomedical)
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02431988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02431988.